Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: David Howe who wrote (1847)	2/25/1999 11:13:00 PM
From: AJAG	Respond to of 10280

To David Howe- Congratulations for giving a succinct explanation of the Sepracor story. We have so many new readers recently that it is good to lay the entire picture out. You know, one of the basic rules of biotech investing is to spread out your risk among multiple product possibilities. You never know which drug candidate will be the big blockbuster. Consider Amgen- it now has a market value of 35 billion based on sales of two blockbusters. In the case of Immunex, everyone was high on their drug PIXY 321, which failed in final tests. However, the next drug, Enbrel is a winner and the stock has soared. With 40 drug possibilities, Sepracor has really spread its risk. By the time they exhaust the 40 patented drug targets, they will have so much cash flow that they can buy more drug possibilities from the smaller cash-starved biotechs. PS- News flash- Fidelity raised its stake in SEPR again, from 12 to 13 percent of the stock (SEC filing). The short sellers are selling to a very deep pocket!